Early endocrine alterations reflect prolonged stress and relate to 1-year functional outcome in patients with severe brain injury

Djordje Marina, Marianne Klose, Annette Nordenbo, Annette Liebach and Ulla Feldt-Rasmussen
Department of Medical Endocrinology PE2131, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark and Traumatic Brain Injury Unit, Department of Neurorehabilitation, Glostrup Hospital, Copenhagen University Hospital, Glostrup, Denmark

Abstract

Objective: Severe brain injury may increase the risk of developing acute and chronic hypopituitarism. Pituitary hormone alterations developed in the early recovery phase after brain injury may have implications for long-term functional recovery. The objective of the present study was to assess the pattern and prevalence of pituitary hormone alterations 3 months after a severe brain injury with relation to functional outcome at a 1-year follow-up.

Design: Prospective study at a tertiary university referral centre.

Methods: A total of 163 patients admitted to neurorehabilitation after severe traumatic brain injury (TBI, N = 111) or non-TBI (N = 52) were included. The main outcome measures were endocrine alterations 3.3 months (median) after the brain injury and their relationship to the functioning and ability of the patients at a 1-year follow-up, as measured by the Functional Independence Measure and the Glasgow Outcome Scale-Extended.

Results: Three months after the injury, elevated stress hormones (i.e. 30 min stimulated cortisol, prolactin and/or IGF1) and/or suppressed gonadal or thyroid hormones were recorded in 68 and 32% of the patients respectively. At 1 year after the injury, lower functioning level (Functional Independence Measure) and lower capability of performing normal life activities (Glasgow Outcome Scale-Extended) were related to both the elevated stress hormones (P < 0.01) and the reduced gonadal and/or thyroid hormones (P < 0.01) measured at 3 months.

Conclusion: The present study suggests that brain injury-related endocrine alterations that mimic secondary hypogonadism and hypothyroidism and that occur with elevated stress hormones most probably reflect a prolonged stress response 2–5 months after severe brain injury, rather than pituitary insufficiency per se. These endocrine alterations thus seem to reflect a more severe disease state and relate to 1-year functional outcome.
chronic subdural haematoma (12) and ischaemic stroke (13), have been related to an increased prevalence of hypopituitarism in some studies but not in others (14, 15).

Previous assessments of the relationship between post-traumatic hypopituitarism and outcomes have shown conflicting results. Some have suggested that hypopituitarism was related to increased disability (16) and a decreased quality of life (16, 17), whereas others have suggested that quality-of-life deficits were more closely associated with intracerebral haemorrhagic lesions than with hypopituitarism per se (18). Peak growth hormone (GH) has been shown to be an independent predictor of poorer outcomes, as measured by rehabilitation scales that evaluate cognition and disability (19), but such relations were recently questioned (20). Reduced testosterone concentrations were also recently described as being related to worse functional outcomes in TBI patients (21, 22), which led the authors to suggest that secondary hypogonadism may limit the pace of recovery during neurorehabilitation.

Based on early reports that suggested a high risk of post-traumatic hypopituitarism, a screening programme was introduced to assess pituitary function at the Department of Neurorehabilitation’s Traumatic Brain Injury Unit at Copenhagen University Hospital, Glostrup. We hypothesised that the results from pituitary hormone assessment in the post-acute phase (i.e. ~3 months post-injury) would relate to functional and cognitive outcomes at 1-year follow-up.

Subject and methods

Subjects

In Denmark, the post-acute rehabilitation of patients with the most severe TBI and non-TBI is centralised at two hospitals, each of which covers ~50% of the Danish population of 5.5 million. Highest priority for admission is given to the most severely brain-injured patients, who are defined as having a Glasgow Coma Scale score of 3–12 in the first days after the cessation of sedation. Patients with a Glasgow Coma Scale score of 12–14 in the first days after the cessation of sedation are also admitted if they have severe focal neurological deficits or are severely agitated.

From 1st June 2007 until 31st May 2011, a total of 272 patients ≥15 years old were admitted to the Department of Neurorehabilitation’s Traumatic Brain Injury Unit in Copenhagen. Patients with known pituitary disease or clinically significant renal disease or who were pregnant or breastfeeding were not considered for inclusion. Twelve patients died, and 51 were discharged to home within 2 months of their initial admission to neurorehabilitation without pituitary testing for unknown reasons. Pituitary assessment was also not performed in 46 patients who had longer stays at the Neurorehabilitation Unit (in 15 patients because of severe agitation and in 31 patients for unknown reasons). Thus, we included 163 patients who had available pituitary hormone measurements: 111 TBI and 52 non-TBI patients. The non-TBI patients included 28 with subarachnoid, intracerebral and non-traumatic haemorrhage, nine with anoxic brain injury, four with occlusion or stenosis of cerebral arteries not causing cerebral infarction, three with brain inflammation (meningitis), two with cerebral oedema, two with sepsis and one each with cerebral infarction, arteriovenous malformation, traumatic fat embolism and central pontine myelinolysis.

The study was approved by the Local Ethical Committee (J.nr. H-D-2009-054) and the Danish Data Protection Agency (J.nr. 30-0831). According to the Danish Act on Processing of Personal Data, a registry study without contact to the persons involved does not require verbal or written consent.

Endocrine function testing and diagnostic criteria for endocrine alterations

Pituitary function testing was performed at a median of 3.3 months (range 2.1–4.9) after the brain injury and related to 1-year outcome data of functioning and ability as part of routine assessment in the department. Hormone assessment was performed between 0800 and 1300 h, and it included baseline measurements of follicle-stimulating hormone (FSH), luteinising hormone (LH), testosterone (males), oestrogen (females), thyroid-stimulating hormone (TSH), free thyroxine (FT4), prolactin and insulin-like growth factor 1 (IGF1). The hypothalamic–pituitary–adrenal axis was assessed using an adrenocorticotropic hormone (ACTH) stimulation test that measured cortisol concentrations at baseline and 30 min after the i.v. administration of 250 μg Synacthen (Defiante Farmacêutica S.A., Funchal, Madeira–Portugal). If patients presented with thirst and/or increased urine volumes, diabetes insipidus was assumed and vasopressin therapy was initiated.

Insufficiencies were defined in relation to local sex- and age-related reference ranges. Secondary hypogonadism in postmenopausal women was defined as inappropriately low gonadotrophins (FSH and LH) for age, in premenopausal women as the presence of...
amenorrhoea or oligomenorrhoea associated with low oestrogen and inappropriately low gonadotrophins and in men as low testosterone associated with inappropriately low gonadotrophins. Secondary hypothyroidism was defined as subnormal FT4 concentration associated with an inappropriately low TSH concentration. Normal reference ranges for the Immulite assay for serum cortisol was based on 100 healthy controls, with reference intervals given as the 2.5th and 97.5th percentiles (23). Thus, adrenal insufficiency was defined as <500 nmol/l 30 min cortisol in response to the Synacthen test, and elevated basal cortisol was described as concentrations of >665 nmol/l and stimulated cortisol as concentrations of >841 nmol/l.

Three of the 52 female patients had been using contraceptive pills, which were discontinued at least 8 weeks prior to endocrine evaluation. At the time of endocrine evaluation, 12 patients were being treated with antipsychotics, 18 with antidepressants, 23 with antiemetics and 37 with antiepileptic drugs (the majority using Gabapentin and Fenytoin (n=19), a minority using Lamotrigin (n=2) and 16 using other antiepileptic medications).

**Function and ability assessments**

Outcome measures of functioning and ability were assessed at admission and discharge from neurorehabilitation and at a 1-year follow-up.

The Functional Independence Measure is a scale consisting of 18 items describing various activities in daily living. These 18 items are further divided into physical (13 items) and cognitive domains (five items). Each item is rated on a seven-point scale from 1 (total assistance needed) to 7 (full independence). The added scores of the 18 items give a minimum total score of 18 and a maximum score of 126. For practical purposes, the overall total scores were divided into three subgroups that indicated the assistance required in order for the individual to carry out daily activities: complete dependency (18–55), moderate dependency (56–74) and low-level dependency to complete independency (75–126). Further, the Functional Independence Measure score can be divided into a motor score, with a maximum of 91, and a cognitive score, with a maximum of 35. The Functional Independence Measure was performed at admission to neurorehabilitation, at discharge and at the 1-year follow-up.

The Glasgow Outcome Scale-Extended is an eight-point scale used to describe the actual functioning of the patient in the period after the brain injury; it refers to independence at and outside the home, different social activities, work capability and return to normal life. For practical purposes, it is divided into two groups: lower scores range from 1 (coma) to 4 (upper severe disability), and higher scores range from 5 (lower moderate disability) to 8 (upper good recovery). Patients with scores from 1 to 4 are more dependent on assistance, whereas patients scoring between 5 and 8 need less assistance performing activities at and outside the home. The Glasgow Outcome Scale-Extended was performed at discharge from neurorehabilitation and at the 1-year follow-up.

In addition, data on post-traumatic amnesia was assessed in the TBI patients using the Galveston Orientation and Amnesia Test. The period of post-traumatic amnesia was defined as the number of days between the date of the TBI and the date when the patient was out of the post-traumatic confused state. Post-traumatic amnesia that lasted for more than 4 weeks indicated a very severe TBI.

**Assays**

The type and performance characteristics of the assays used for the hormone measurements are shown in Supplementary Table 1, see section on supplementary data given at the end of this article.

**Statistical analyses**

Categorical data are presented as n (%) and continuous as mean (±S.D.) if normally distributed and otherwise as median (range).

Categorical data were compared by a $\chi^2$ test. Cramer’s V coefficient was used to evaluate associations between two nominal variables. Between-group comparisons of normally distributed continuous data were analysed by Student’s t-test or by Mann–Whitney U test. Regression analyses were conducted to analyse the relation between outcome measures (Functional Independence Measure and Glasgow Outcome Scale-Extended) and dependent covariates (injury characteristics, medication, including analgesics, antidepressants and antiepileptic drugs, and hormonal hypo/hyper secretion). Basal and stimulated cortisol concentrations of the patients were compared to 100 healthy persons in which a Synacthen test was performed and cortisol was measured by Immulite assay (23).

Associations were performed on the pooled data from the TBI and non-TBI groups, because no significant difference was observed in the prevalence of hormone alterations between the groups. A difference was
considered significant when $P<0.05$. Statistical analyses were performed by SAS version 9.1 (SAS Institute, Inc., Cary, NC, USA).

### Results

#### Patient characteristics

The patients' characteristics at admission are presented in Table 1. The Synacthen test results were missing for 12 patients (7%), whereas other hormonal measurements were missing in a minor proportion of the patients (Table 1). Patients who fulfilled the inclusion criteria but were not included ($n=109$) did not differ from those included ($n=163$) in terms of sex ($P=0.66$) and age ($P=0.67$), but they were less affected, as assessed by their shorter post-traumatic amnesia lengths ($P=0.001$), higher Glasgow Coma Scale scores at admission ($P=0.03$) and better Functional Independence Measure total, physical and cognitive scores one year after admission (all $P=0.02$).

#### Prevalence of endocrine alterations

The prevalence of hormonal alterations at a median of 3.3 months after brain injury in the TBI and non-TBI patients is shown in Fig. 1. There were no significant differences in the prevalence of endocrine alterations between the TBI and non-TBI patients. The upper six panels in Fig. 1 demonstrate possible pituitary deficiencies. Hormonal alterations similar to secondary hypogonadism (24% of the TBI patients and 22% of the non-TBI patients) and hypothyroidism (9% of the TBI patients and 16% of the non-TBI patients) were the most commonly observed, whereas other deficiencies were observed in up to 5% of the TBI and non-TBI patients. The lower four panels in Fig. 1 show the prevalence of elevated stress hormones.

### Table 1

Baseline characteristics of the included patients with traumatic brain injury (TBI) and non-TBI, with additional data on hormonal assessment. Data are given as number (%) or mean (s.d.)/median (range, 10–90%).

<table>
<thead>
<tr>
<th></th>
<th>TBI</th>
<th>Non-TBI</th>
</tr>
</thead>
<tbody>
<tr>
<td>$n$</td>
<td>111</td>
<td>52</td>
</tr>
<tr>
<td>Gender, men (%)</td>
<td>83 (75%)</td>
<td>28 (54%)</td>
</tr>
<tr>
<td>Age at admission (years)</td>
<td>42.7 (18.5)</td>
<td>47.9 (16.0)</td>
</tr>
<tr>
<td>Glasgow Coma Scale score at admission</td>
<td>10.2 (3.1)</td>
<td>11.3 (2.3)</td>
</tr>
<tr>
<td>Time from trauma to neurorehabilitation (days)</td>
<td>20.7 (13.0)</td>
<td>28.6 (18.6)</td>
</tr>
<tr>
<td>Length of neurorehabilitation (days)</td>
<td>113.1 (67.2)</td>
<td>93.7 (40.5)</td>
</tr>
<tr>
<td>CT/MR finding (TBI)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Traumatic subarachnoid haemorrhage</td>
<td>64 (57%)</td>
<td>/</td>
</tr>
<tr>
<td>Cranial fracture</td>
<td>42 (38%)</td>
<td>/</td>
</tr>
<tr>
<td>Shearing lesions</td>
<td>30 (27%)</td>
<td>/</td>
</tr>
<tr>
<td>Cerebral oedema</td>
<td>26 (23%)</td>
<td>/</td>
</tr>
<tr>
<td>Cause of injury (non-TBI)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subarachnoid haemorrhage</td>
<td>/</td>
<td>16 (31%)</td>
</tr>
<tr>
<td>Intracerebral haemorrhage</td>
<td></td>
<td>12 (23%)</td>
</tr>
<tr>
<td>Anoxic brain injury</td>
<td>/</td>
<td>9 (17%)</td>
</tr>
<tr>
<td>Other</td>
<td>15 (25%)</td>
<td>/</td>
</tr>
<tr>
<td>Functional Independence Measure score at admission</td>
<td>18 (18–44)</td>
<td>18 (18–25)</td>
</tr>
<tr>
<td>Post traumatic amnesia, days (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt; 4 weeks</td>
<td>98 (88%)</td>
<td>/</td>
</tr>
<tr>
<td>&lt; 4 weeks</td>
<td>13 (12%)</td>
<td>/</td>
</tr>
<tr>
<td>Number of patients with pituitary assessment (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synacthen test, including basal cortisol</td>
<td>102/111 (92%)</td>
<td>49/52 (94%)</td>
</tr>
<tr>
<td>Prolactin</td>
<td>109/111 (98%)</td>
<td>50/52 (96%)</td>
</tr>
<tr>
<td>Insulin-like growth factor 1 (IGF1)</td>
<td>109/111 (98%)</td>
<td>50/52 (96%)</td>
</tr>
<tr>
<td>Gonadal hormones</td>
<td>109/111 (98%)</td>
<td>50/52 (96%)</td>
</tr>
<tr>
<td>Free thyroxine (FT4)</td>
<td>110/111 (99%)</td>
<td>50/52 (96%)</td>
</tr>
<tr>
<td>Median concentration (range) of hormonal measurement</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stimulated 30 min cortisol</td>
<td>773 nmol/l (566–1240)</td>
<td>774 nmol/l (491–1280)</td>
</tr>
<tr>
<td>Prolactin</td>
<td>0.61 nmol/l (0.15–4.9)</td>
<td>0.59 nmol/l (0.16–10.6)</td>
</tr>
<tr>
<td>IGF1</td>
<td>229 mg/l (64–486)</td>
<td>222 mg/l (28–461)</td>
</tr>
<tr>
<td>Testosterone (males)</td>
<td>12 nmol/l (1.0–28.0)</td>
<td>9.9 nmol/l (0.2–17.5)</td>
</tr>
<tr>
<td>FT4</td>
<td>14.2 pmol/l (6.9–19.1)</td>
<td>14.7 pmol/l (9.7–26.4)</td>
</tr>
</tbody>
</table>

CT, computerized tomography; MR, magnetic resonance.
degree of dependency. Functional Independence Measures improved significantly during the rehabilitation period in both the TBI and non-TBI patients (Fig. 2). Thus, significantly fewer patients had a high degree of dependency at the 1-year follow-up as compared to baseline (i.e. at admission to neurorehabilitation) in both the TBI and non-TBI patients ($P<0.01$) (Table 2). In the TBI group, Functional Independence Measure scores were missing for 18 patients at the 1-year follow-up. In the non-TBI group, Functional Independence Measure scores were missing for one patient at admission, two patients at discharge and 12 patients at the 1-year follow-up visit (Table 2).

Glasgow Outcome Scale-Extended

At discharge, 72% of the TBI patients and 86% of the non-TBI patients had a very low Glasgow Outcome Scale-Extended score, which indicated a low degree of independent activity (Table 2). This was ameliorated at the 1-year follow-up visit in a significant number of patients in the TBI group ($P<0.05$). In the TBI group, Glasgow Outcome Scale-Extended scores were missing for 18 patients at the 1-year follow-up (Table 2). In the non-TBI group, Glasgow Outcome Scale-Extended scores were missing for one patient at discharge and 12 patients at the 1-year follow-up (Table 2).

Relationship between early endocrine alterations and functional outcome measures at the 1-year follow-up

Worse Functional Independence Measure total, cognitive and physical scores at 1 year were related to lower Glasgow Coma Scale scores at referral and a need for longer rehabilitation ($P<0.001$; $\beta_{total} < -0.23$; $\beta_{cognitive} < -0.05$; $\beta_{physical} < -0.16$) but not to shearing lesions or medical treatment with antiepileptic, antidepressant or analgesic drugs (all $P>0.22$). Worse Functional Independence Measure scores were also related to secondary hypogonadism ($P<0.02$; $\beta_{total} < -20$; $\beta_{cognitive} < -4.5$; $\beta_{physical} < -14$) and increased stress hormones ($P<0.02$; $\beta_{total} < -13$; $\beta_{cognitive} < -4$; $\beta_{physical} < -15$). Both secondary hypogonadism ($P=0.02$; $\beta=16$) and increased stress hormones ($P=0.02$; $\beta=14$) remained independently related to worse Functional Independence Measure scores in multivariate analyses after adjusting for the length of rehabilitation needed ($P\leq0.01$; $R^2=0.23$).

A low capability for returning to normal life activities, as indicated by a low Glasgow Outcome-Extended score at 1 year, was more frequent in patients with a lower Glasgow Coma Scale score at referral and a need for longer rehabilitation ($P<0.01$; $R^2=0.23$).

Functional Independence Measure

Low median Functional Independence Measure total, motor and cognitive scores at admission were in agreement with very severely injured patients that had a high median Functional Independence Measure total, motor and cognitive scores at admission were in agreement with very severely injured patients that had a high
rehabilitation ($P<0.001$) but not to shearing lesions or medical treatment with antiepileptic, antidepressant or analgesic drugs ($P=0.32$). A low Glasgow Outcome-Extended score was also related to reduced gonadal and/or thyroid hormones ($P=0.04$; Cramer’s $V=−0.17$) and elevated stress hormones ($P=0.006$; Cramer’s $V=−0.23$). In multivariate analyses, adjusting for the length of rehabilitation needed increased stress hormones ($P=0.01$) but not secondary hypogonadism ($P=0.17$), which remained independently related to a worse Glasgow Outcome-Extended score at 1 year.

**Discussion**

In the present cohort of 163 patients assessed at a median of 3.3 months after a severe acquired brain injury, the most prevalent hormonal alterations were increased concentrations of stress-related hormones, followed by decreased gonadal and thyroid hormones, which concomitantly presented in 26% of the patients.

Similar endocrine alterations have been reported both in patients with brain injury (4, 5, 6) and in patients with other causes of acute and severe illness (24). Although in some cases endocrine alterations may be attributed to primary or secondary injury to the hypothalamus or pituitary gland, acute severe illness involves major stress to the organism, and increased ACTH, cortisol, GH and prolactin concentrations, together with low testosterone and low triiodothyronine syndrome, have all been described as being part of important adaptive responses in the early phases following trauma, surgery and severe medical illness (24). However, distinct hormonal secretion patterns are also to be expected in the chronic phase of critical illness and in the subsequent recovery phase with the restoration of peripheral sensitivity and the loss of central drive (25). Patients included in the present study were either in the chronic phase of critical illness or in the recovery phase at the time of testing. Thus, although all of the patients still required neurorehabilitation, the cohort remained inhomogeneous, which probably explains some of the observed inter-individual differences.

A Synacthen test was routinely performed in order to diagnose hypoadrenalism. At 3 months, hypoadrenalism was only registered in two non-TBI patients. Further, up to 5% of the patients in both groups had decreased basal cortisol values, which were defined as baseline total cortisol <2.5th percentile from that of healthy subjects. During critical illness, glucocorticoid secretion markedly increases and relates to stress activation of the hypothalamic–pituitary–adrenal axis (25) and reduced cortisol breakdown as a result of the suppressed expression and activity of cortisol-metabolising enzymes (26). The increase is, however, not necessarily discernible when only the total cortisol concentration is measured. In a study by Hamrahian et al. (27), nearly 40% of critically ill patients with hypoproteinaemia had subnormal total cortisol concentrations, even though their adrenal function was normal, as measured by free cortisol concentrations. Thus, lower cortisol binding globulin (CBG) concentrations (28) may have led to low cortisol concentrations in a subset of our patients, even though they responded appropriately to Synacthen stimulation. Furthermore, blood sampling was performed from 0800 to 1300 h, which could have influenced results because of circadian hormonal rhythms. If this was the case, we may have underestimated the prevalence of elevated basal cortisol concentrations rather than overestimating them.

It is noteworthy that one-third of the patients in the present cohort had a 30 min cortisol concentration above that expected in healthy people, which suggests a
**Table 2** Distribution of scores in traumatic brain injury (TBI) and non-TBI patients. The table presents the number of patients with baseline and/or discharge, as well as follow-up Functional Independence Measure total scores and Glasgow Outcome Scale-Extended scores. Both scores were further divided in scoring subgroups depending on the actual level of the patients’ functioning.

<table>
<thead>
<tr>
<th>Time of measurement</th>
<th>TBI</th>
<th>Non-TBI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Admission</td>
<td>Discharge</td>
</tr>
<tr>
<td>Functional Independence Measure Complete dependency</td>
<td>104/111 (94%)</td>
<td>45/111 (41%)</td>
</tr>
<tr>
<td>Moderate dependency</td>
<td>3/111 (3%)</td>
<td>8/111 (7%)</td>
</tr>
<tr>
<td>Low dependency to complete independency</td>
<td>4/111 (3%)</td>
<td>58/111 (52%)</td>
</tr>
<tr>
<td>Glasgow Outcome Scale-Extended</td>
<td>Not done</td>
<td>80/111 (72%)</td>
</tr>
<tr>
<td>Lower moderate disability to upper good recovery</td>
<td>Not done</td>
<td>31/111 (28%)</td>
</tr>
</tbody>
</table>

*In the TBI group, Functional Independence Measure and Glasgow Outcome Scale-Extended scores were missing for 18 patients at the 1-year follow-up (two patients died before attending the follow-up visit, one patient attended the visit but that patient's score was not recorded, and 15 patients did not attend the follow-up visit for unknown reasons).
*In the non-TBI group, Functional Independence Measure scores were missing for one patient at admission, two patients at discharge, and 12 patients at the 1-year follow-up visit (three patients died before attending the follow-up visit, one patient attended the follow-up visit but that patient's score was not recorded, and eight patients did not attend the follow-up visit for unknown reasons), whereas Glasgow Outcome Scale-Extended scores were missing for one patient at discharge and for the same number of patients at the 1-year follow-up as described for the Functional Independence Measure scores.
*Three scoring groups (scores in parentheses) represent the actual need for help in performing basic daily activities. Patients in the lowest scoring group were completely dependent on assistance during the day. On the contrary, patients in the highest scoring group needed less assistance.
*A significant number of patients switched from the lower-scoring group (at discharge) to the higher-scoring group (at the 1-year follow-up) (P < 0.01).
*A significant number of patients switched from the complete dependency group (at admission) to the low dependency/complete independency group (at the 1-year follow-up) (P < 0.05).

prolonged stress response with glucocorticoid hyperactivation. Unfortunately, neither ACTH nor CBG were measured, and thus no correlations between total and free cortisol concentrations could be made. Finally, the documented use of the Synacthen test is apt for the assessment of hypo- and not hyperactivation of the adrenal gland. The original purpose of the study was to assess hypofunction; thus, measurements of such factors as 24-h urine cortisol, which would have been preferable for assessing hyperactivation (29), were not included.

Increased prolactin was the most commonly observed endocrine alteration. Hyperprolactinaemia is a well-known phenomenon in the acute phase of a brain injury that may persist in 31% of patients during rehabilitation (30), and it was reported in up to 47% of the TBI patients who had other endocrine failures during long-term follow-up (31). Although hyperprolactinaemia may indicate pituitary stalk and/or hypothalamic injury, prolactin is one of the first hormones to increase in acute phases of severe illness, whereas prolactin is no longer as high in chronic phases (24).

In acute and chronic phases of critical illness, IGF1 concentrations tended to be low (32). However, Kopczak et al. (33) showed that 14% of their patients had elevated IGF1, whereas 6% had reduced IGF1 concentrations, as measured at a median of 7 weeks after the TBI or subarachnoid haemorrhage. This was in keeping with our data of commonly registered elevated IGF1. However, it is not clear whether increased IGF1 should be considered part of neuroprotection (34) or as a result of the insulin resistance and hyperglycaemia that are commonly observed during prolonged critical illness (35). A concomitant assessment of GH concentrations might have clarified this further.

Endocrine alterations similar to secondary hypogonadism and hypothyroidism were observed in 23 and 11% of the patients respectively. Similar findings have previously been observed in patients with brain injury (4, 5, 11) but also in patients with critical illness resulting from other causes and without a history of acquired brain injury (24). It is well established that prolonged critical illness alters the physiology of the reproductive axis with decreased testosterone concentrations and reduced or low to normal gonadotrophins (36); these patterns have also been observed for the thyroid axis (24). The most likely explanation for these endocrine alterations in severe prolonged illness was suggested to be impairment of the pulsatile component of pituitary hormones, such as the gonadal axis (24), but it may also involve reduced
hypothalamic stimulation of trophic hormones, which in
turn leads to reduced stimulation of the target organ (25).

Because secondary hypogonadism and hypothyroid-
ism were present concomitant with elevated stress
hormones in 26% of the patients, we suggest that these
endocrine alterations were a result of the prolonged stress
response in the period after the severe brain injury and not
a result of hypothalamo-pituitary injury.

Some recent outcome studies have indicated that post-
traumatic hypopituitarism has clinical significance
because it impacts both health-related quality of life and
lipid status (17), but the findings have been inconsistent
(20, 37). Ælfarson et al. (37) tested 51 patients with severe
TBI for 2–10 years after the initial trauma, which is longer
than the present study, but they showed no relationship
between hypopituitarism and worse psychological, cogni-
tive or motor functioning in the longer term. In the present
study, both secondary hypogonadism and increased stress
hormones were related to worse 1-year follow-up scores
on the Functional Independence Measure, which is well
known and widely used in rehabilitation settings. A recent
non-randomised retrospective study in TBI patients
suggested that reduced testosterone levels at admission
were related to lower admission scores, less change in scores
on the Functional Independence Measure and longer hospitalisation (21). Other authors have suggested that
hypogonadism may limit the pace of recovery during
rehabilitation (22) because of the well-known effects of
testosterone on muscle mass and strength, cognition and
perception of the quality of life. Whether the same pattern
of action can be applied to people with acquired severe
brain injuries remains to be investigated. Kopczak et al. (33)
went a step further and treated 13 male patients after TBI
or subarachnoid haemorrhage with testosterone replace-
ment. The Barthel index (a measurement of independence
and recovery) and haemoglobin concentrations before
and after treatment were measured, and haemoglobin
had increased in four patients in 4 weeks >2 g/dl
(1.24 mmol/l), which was a surrogate sign of testosterone
replacement benefit (33). However, the distinction
between primary and secondary hypogonadism was
unclear, because gonadotrophins were not measured.
Further studies are needed to predict if male patients
diagnosed with hypogonadism after an acquired brain
injury, irrespective of its cause, would achieve a better
neurorehabilitation outcome with testosterone treatment.

Low Glasgow Outcome Scale-Extended scores were
significantly improved from discharge to the 1-year
follow-up, which implies that more patients became
capable of returning to normal activities both inside and
outside of their homes. However, low Glasgow Outcome
Scale-Extended scores were more frequent in patients with
reduced gonadal and/or thyroid hormones and increased
stress hormones, whereas only increased stress hormones
remained independently related to a worse Glasgow
Outcome Scale-Extended score at the 1-year follow-up.
Santarsieri et al. (38) recently measured cortisol in the
cerebrospinal fluid of the TBI patients and showed
persistently elevated cortisol during the first 6 days after
trauma, which was associated with poorer outcomes, as
measured by Glasgow Outcome Scale scores and Functional
Independence Measure cognitive scores 6 months after the
injury. Recently, pituitary abnormalities in 27% of patients
3–6 months after a subarachnoid haemorrhage were
significantly related to lower median Glasgow Outcome
Scale scores at follow-up, with more prevalent endocrine
abnormalities occurring when bleeding sites were closer
to the hypothalamus (39). In contrast to the present and
previously mentioned studies, other authors did not find
an association between endocrine alterations and Glasgow
Outcome Scale-Extended score measures (37, 40) or other
quality-of-life questionnaires (18, 20).

Some limitations of the present study should be
addressed. GH stimulation tests were not part of the routine
screening programme at the neurorehabilitation centre,
and GH measurements are thus not available, although they
could have potentially clarified the significance of the
observed changes in IGF1 values. BMI has been shown to
influence both GH and IGF1, the latter being decreased with
BMI exceeding 32.5 kg/m² as well as with low BMI (41).
Unfortunately, at the time of testing, BMI was not available
for our patients, and we could thus not correct for it. Another
limitation is the aetiologic difference with variable prog-
noses and influence on the Functional Independence
Measure score. However, the number of patients within
each aetiologic subgroup was too small for subgroup
analyses. Although the patients in the present study
represented a heterogeneous group, especially among the
non-TBI patients, the vast majority had very severe trauma,
which was indicated by very low physical and cognitive
scores at the time of admission to neurorehabilitation, ~3
weeks after the initial trauma. Finally, the influence of
medications such as antidepressants, antipsychotics and
antiemetics could be additional factors for the observed
frequency of such conditions as hyperprolactinaemia.

In the present study, hormonal assessment was
performed ~3 months after injury. The development of
post-traumatic hypopituitarism later than 3 months after
injury has been suggested (6). It remains speculative,
however, if such new deficiencies would have affected
our data. The insufficiencies reported in the present study were retested by repeat measurement ~12 months after the injury (D Marina, M Klose and U Feldt-Rasmussen, unpublished data). Most had resolved, and none of the patients had any replacements initiated after the 3-month testing.

In conclusion, the present study suggested that endocrine alterations similar to secondary hypogonadism and hypothyroidism at a median of 3.3 months after an acquired severe brain injury most probably reflected a prolonged stress response rather than brain damage per se. Accordingly, not only secondary hypogonadism and hypothyroidism but also elevated stress hormones were related to worse 1-year functional outcomes.

Thus, we suggest that post-brain injury endocrine alterations are not necessarily a consequence of hypothalamic or pituitary damage; rather, they may represent physiological stress adaptations to acute critical illness, with a subsequent prolonged stress response at least 3 months post-injury. Therefore, routine pituitary assessment in the early phases (e.g. within a year) after acquired brain injury should be limited to patients that present with typical clinical features suggestive of hypopituitarism (4, 7).

Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/EJE-14-1152.

Declaration of interest
U Feldt-Rasmussen received unrestricted research and travel grants and speaker's fees from Novartis and Ipsen, research grants, speaker's fees and advisory board honoraria from Pfizer and a research grant from Arvid Nilsson's Fund. M Klose received an unrestricted research grant from Novo Nordisk and speaker fees from Pfizer and Novartis. D Marina, A Nordenbo and A Liebach have nothing to disclose.

Funding
This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Author contribution statement
D Marina wrote the paper; A Nordenbo and A Liebach were supervisors during the whole period of the study and collected the data; M Klose and U Feldt-Rasmussen initiated the study and supervised all aspects of the process; all authors contributed to the writing of the paper.

Acknowledgements
U Feldt-Rasmussen's research salary was supported by a grant from Arvid Nilsson's fund. We thank Lars Westergaard for his assistance in collecting data and constructing the patient database used in the present study.

References